### Recent Research Progress on Oral Minoxidil: From Antihypertensive Drug to a “New Weapon” for Hair Loss Treatment
Minoxidil was originally an oral medication for hypertension. During clinical use, physicians discovered an interesting side effect—it promoted hair growth. In the 1980s, topical minoxidil was approved by the U.S. FDA for the treatment of androgenetic alopecia (commonly known as “seborrheic alopecia”) and has remained a first-line over-the-counter therapy to this day. However, topical formulations have drawbacks such as inconvenient application, scalp irritation, and poor absorption in some patients. In recent years, **low-dose oral minoxidil (LDOM)** has re-emerged as a research focus, becoming a hot topic in the field of hair loss treatment. This article, based on the latest evidence-based medical evidence, will take you through the research progress on oral minoxidil.
### Mechanism of Action and Dosage of Oral Minoxidil
Oral minoxidil is metabolized by the liver into its active form, minoxidil sulfate. This active form primarily prolongs the anagen (growth) phase of hair by activating potassium channels, dilating blood vessels, and increasing blood supply to hair follicles. Additionally, it upregulates the expression of growth-promoting factors (such as VEGF) in hair follicle cells. Compared with topical use, the oral route avoids localized scalp irritation, and the drug, after systemic circulation, can be uniformly distributed to hair follicles—potentially more effective for hard-to-reach areas such as the occipital scalp.
The standard “low-dose” regimen typically refers to **0.625 mg to 5 mg per day**, far lower than the original antihypertensive dosage (10–40 mg per day). Many studies start with 2.5 mg or 5 mg, but Asian populations may begin at a lower dose (0.625–1.25 mg) to reduce side effects.
### Latest Research Progress: Indications and Efficacy Data
**1. Androgenetic Alopecia (Most Common Indication)**
In 2023, *JAMA Dermatology* published a randomized, double-blind, placebo-controlled trial involving 120 men with androgenetic alopecia, who were given either 5 mg/day of oral minoxidil or a placebo. After 24 weeks, the oral group showed significantly superior results in vertex hair density (an increase of approximately 20 hairs per cm²) and patient self-assessment compared to placebo, and scalp itching and other discomforts were markedly reduced. Another 2024 meta-analysis, incorporating 8 studies and over 600 patients, concluded that oral minoxidil (1.25–5 mg/day) was non-inferior to standard 5% topical minoxidil after 6 months of treatment, and may be particularly more effective for frontal hair loss areas.
**2. Female Pattern Hair Loss**
Female patients with hair loss also respond well to oral minoxidil. An open-label study published in the *British Journal of Dermatology* in 2022 showed that 61 women taking 1.25 mg/day of oral minoxidil experienced an average increase in hair density of 18% after 6 months, and 90% of patients reported improvement in hair loss. Notably, oral regimens in women can avoid accidental contact of topical products with facial hair, thereby reducing unwanted hypertrichosis side effects.
**3. Alopecia Areata and Other Non-Scarring Alopecias**
Oral minoxidil has also been explored in alopecia areata (especially mild-to-moderate cases with shorter disease duration). A small 2023 prospective study (n=30) using 2.5 mg/day found that approximately 60% of patients experienced hair regrowth after 6 months, but the rate of complete regrowth was low (around 20%). The current level of evidence is weak, and it is not recommended as a first-line treatment for alopecia areata.
### Safety: Side Effects and Precautions
The most commonly reported side effects of oral minoxidil include:
– **Hypertrichosis**: Increased hair growth on the face and limbs, with an incidence of approximately 5–15%, dose-dependent, and usually reversible upon dose reduction or discontinuation.
– **Edema**: Ankle or eyelid edema occurs in about 2–5% of patients; diuretics or a low-salt diet can alleviate symptoms.
– **Hypotension and Palpitations**: Rare but requires caution, especially during the initiation phase or at higher doses (>5 mg/day). Patients with cardiovascular diseases (e.g., arrhythmia, history of hypotension) should use it with caution.
– **Other**: Headache, dizziness, and nausea occur at lower rates.
A 2024 systematic review indicated that oral minoxidil is generally well tolerated, with severe adverse events (such as pericardial effusion) being extremely rare (<0.1%), and occurring primarily in cases of very high doses (>10 mg/day) or in patients with renal failure. Nevertheless, blood pressure, heart rate, and renal function must be assessed before use, and treatment should start at a low dose with gradual adjustment.
### Future Research Directions and Limitations
Currently, oral minoxidil has not been approved for hair loss treatment by any major regulatory agency (e.g., U.S. FDA, China NMPA) and is considered an **off-label use**. Researchers are working to:
– Determine optimal dosing regimens (considering sex, weight, and ethnic differences);
– Develop sustained-release formulations to reduce side effects;
– Evaluate combination therapy with low-dose finasteride or dutasteride.
### Summary
Low-dose oral minoxidil (0.625–5 mg/day), as a new option for hair loss treatment, has demonstrated efficacy in improving androgenetic alopecia and relatively good safety in multiple high-quality studies. **However, it is not suitable for everyone**—pregnant or breastfeeding women, and individuals with uncontrolled hypertension or hypotension should avoid it. For those considering this treatment, it is essential to do so under the guidance of a dermatologist or relevant specialist, and never self-purchase or self-administer.
—
**For reference only and does not constitute medical advice**